Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Trellis Bioscience raises $9 million in Series C funding to advance clinical development of Calpurbatug (TRL1068), targeting antibiotic-resistant infections. New and existing investors including AMR Action Fund and New Science Ventures participated.
PRIVATEJul 16, 2026•24 days ago
Amount Raised
$9 Million
Round Type
Series C
Redwood CityBiotechnologyHealth Care
Investors
The Doctor Group Of DallasAmr Action FundEaston CapitalNew Science Ventures
Description
Trellis Bioscience announced the closing of a $9 million Series C financing aimed at supporting the Phase 2 trial of Calpurbatug (TRL1068) for chronic prosthetic joint infections. The funding attracted participation from both existing and new investors. This investment solidifies Trellis's total equity funding at approximately $35 million, complemented by substantial non-dilutive grant support.
Company Information
Company
Trellis Bioscience
Location
Redwood City, California, United States
About
Trellis Bioscience is a clinical-stage biotechnology company focused on developing native human monoclonal antibodies (mAbs) to treat intractable infectious diseases. The company is currently advancing its investigational treatment, calpurbatug (TRL1068), for chronic prosthetic joint infections. With substantial funding from various investors, Trellis aims to redefine the treatment for antibiotic-resistant infections. They utilize innovative approaches to combat the challenges posed by bacterial biofilm in infections.
Related People
Suggested for you
2 contacts
Verified contactsStefan, President & CEO hidden
Predictive Intelligence
Strategic
ML-powered predictions for Trellis Bioscience's next move
Redwood CityBiotechnologyHealth Care